BackgroundImmune check point inhibitors (ICIs) are standard treatment for patients with non-small cell lung cancer (NSCLC). Nearly a decade has passed since nivolumab was approved by the FDA for NSCLC patients. However. long-term outcomes and clinical features remain unclear for individual cases. https://www.parisnaturalfoodes.shop/product-category/deodorant-curator/